Comparison of outcomes of haploidentical donor hematopoietic stem cell transplantation supported by third-party cord blood with HLA-matched unrelated donor transplantation.


Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 30 11 2019
medline: 28 4 2021
entrez: 29 11 2019
Statut: ppublish

Résumé

Previous study indicated that co-infusion of cord blood cells may potentially improve the outcome of haploidentical donor (HID) transplantation. In this study, we analyzed the outcomes of patients who underwent HID transplantation supported by cord blood when compared with HLA-matched unrelated donor (URD) transplantation. Starting in 2015, 40 patients with hematopoietic malignancies underwent HID transplantation and 26 patients underwent URD transplantation. Hematopoietic recovery, the incidences of grade II-IV acute graft-versus-host disease (GVHD) and chronic GVHD was comparable in the two groups. At two year, the relapse risk in HID group was significantly lower than in URD group (RR 4.630; 95%CI, 1.081-19.839;

Identifiants

pubmed: 31777304
doi: 10.1080/10428194.2019.1695053
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

840-847

Commentaires et corrections

Type : CommentIn

Auteurs

Hairong Lyu (H)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Wenyi Lu (W)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Jianfeng Yao (J)

Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, PR China.

Xia Xiao (X)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Qing Li (Q)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Jia Wang (J)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Juan Mu (J)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Yao Qi (Y)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Haibo Zhu (H)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Yili Jiang (Y)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Xin Li (X)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Juanxia Meng (J)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Ting Yuan (T)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Xiaoyuan He (X)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Erlie Jiang (E)

Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, PR China.

Mingzhe Han (M)

Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, PR China.

Mingfeng Zhao (M)

Department of Hematology, Tianjin First Center Hospital, Tianjin, PR China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH